Vanguard reports 0 shares of Quest Diagnostics
Rhea-AI Filing Summary
The Vanguard Group amended its Schedule 13G for Quest Diagnostics Inc. The filing states that, following an internal realignment described in the filing, The Vanguard Group reports 0 shares beneficially owned of Quest Diagnostics common stock and 0% of the class as of 03/13/2026. The amendment explains that certain subsidiaries and business divisions will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard disaggregated holdings and reports zero beneficial ownership after internal realignment.
The filing documents an internal realignment effective January 12, 2026 and relies on SEC Release No. 34-39538 for disaggregated reporting. It explicitly lists 0 shares and 0% beneficial ownership of Quest Diagnostics common stock in the amendment.
This is an administrative ownership disclosure reflecting reporting structure changes rather than a purchase or sale. Subsequent filings from Vanguard or the named subsidiaries may show separate beneficial positions for related entities.
FAQ
What does Vanguard's Schedule 13G/A for Quest Diagnostics (DGX) state?
Why did The Vanguard Group change its reporting for DGX?
Who signed the Schedule 13G/A amendment for Vanguard and when?
AI-generated analysis. How Rhea-AI works. Not financial advice.